Search results
Results From The WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
Rotarix (human rotavirus vaccine, live attenuated) Shingrix (for Zoster Vaccine Recombinant, Adjuvanted) Synflorix (pneumococcal polysaccharide conjugate vaccine (adsorbed)) Twinrix (for combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen)) Typherix (typhoid vaccine (purified polysaccharide ...
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4][5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
May 20, 2024 at 4:27 PM. By Jonathan Stempel. (Reuters) -GSK has been sued by an independent Connecticut laboratory that accused the drugmaker of defrauding the U.S. government and taxpayers by ...
For premium support please call: 800-290-4726 more ways to reach us more ways to reach us
List of largest biomedical companies by revenue. The following is a list of independent pharmaceutical, biotechnology and medical companies listed on a stock exchange (as indicated) that have generated a revenue of at least US$ 10 billion, ranked by their revenue in the respective financial year. It does not include biotechnology companies that ...
This page was last edited on 20 December 2023, at 21:36 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply.
Vir collaborated with GlaxoSmithKline to make various refinements to S309, resulting in sotrovimab. [17] Sotrovimab has been engineered to possess an Fc LS mutation (M428L/N434S) that confers enhanced binding to the neonatal Fc receptor [18] resulting in an extended half-life and potentially enhanced drug distribution to the lungs. [19]